利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.015 秒)

    Method for producing fibronectin and fibrinogen compositions using a polyalkylene glycol and glycine or &bgr;-alanine
    1.
    发明授权
    Method for producing fibronectin and fibrinogen compositions using a polyalkylene glycol and glycine or &bgr;-alanine 有权
    使用聚亚烷基二醇和甘氨酸或β-丙氨酸制备纤连蛋白和纤维蛋白原组合物的方法

    公开(公告)号：US06579537B2

    公开(公告)日：2003-06-17

    申请号：US09502029

    申请日：2000-02-10

    申请人： Thomas Seelich ,  Ralf Broermann

    发明人： Thomas Seelich ,  Ralf Broermann

    IPC分类号： A61K3516

    CPC分类号： A61L24/106 ,  C07K14/755 ,  C07K14/78

    摘要： A method of producing a pharmaceutical preparation comprising fibronectin and fibrinogen is disclosed. The method involves admixing into a starting solution of fibrinogen and fibronectin, in a single step, a precipitating composition comprising a polyalkylene glycol and at least one of glycine and &bgr;-alanine which forms a precipitate. Next, the precipitate is collected and a pharmaceutical preparation is prepared from the precipitate. The pharmaceutical preparation has a fibronectin:fibrinogen ratio from about 0.02 to about 0.2.

    摘要翻译： 公开了一种制备包含纤连蛋白和纤维蛋白原的药物制剂的方法。 该方法包括在单一步骤中混合纤维蛋白原和纤连蛋白的起始溶液，沉淀组合物包含聚亚烷基二醇和形成沉淀物的甘氨酸和β-丙氨酸中的至少一种。 接着，收集沉淀物，从沉淀物制备药物制剂。 药物制剂具有约0.02至约0.2的纤连蛋白：纤维蛋白原比例。

    Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
    2.
    发明授权
    Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method 有权
    用于制备基于纤维蛋白原和纤连蛋白的制剂的方法以及根据该方法可获得的蛋白质组合物

    公开(公告)号：US07241603B2

    公开(公告)日：2007-07-10

    申请号：US10300388

    申请日：2002-11-19

    申请人： Thomas Seelich ,  Ralf Broermann

    发明人： Thomas Seelich ,  Ralf Broermann

    IPC分类号： C12N9/00

    CPC分类号： A61L24/106 ,  C07K14/755 ,  C07K14/78

    摘要： A method for producing protein compositions comprising fibrinogen and fibronectin is disclosed, wherein a fibrinogen and fibronectin-containing starting solution is treated with a precipitating composition which comprises two different components that modify the solubility of fibrinogen and/or fibronectin, so that in a single-step precipitation a precipitate is formed which comprises fibrinogen and fibronectin, and the precipitate formed optionally is further treated by methods known per se.

    摘要翻译： 公开了一种用于生产包含纤维蛋白原和纤连蛋白的蛋白质组合物的方法，其中含有纤维蛋白原和纤连蛋白的起始溶液用沉淀组合物处理，所述沉淀组合物包含改变纤维蛋白原和/或纤连蛋白的溶解度的两种不同组分， 形成沉淀物，其包含纤维蛋白原和纤连蛋白，并且任选地形成的沉淀物通过本身已知的方法进一步处理。

    Tissue adhesive
    3.
    发明授权
    Tissue adhesive 失效
    组织粘合剂

    公开(公告)号：US4298598A

    公开(公告)日：1981-11-03

    申请号：US118656

    申请日：1980-02-04

    申请人： Otto Schwarz ,  Yendra Linnau ,  Franz Loblich ,  Thomas Seelich

    发明人： Otto Schwarz ,  Yendra Linnau ,  Franz Loblich ,  Thomas Seelich

    IPC分类号： A61L24/00 ,  A61K35/14 ,  A61K38/16 ,  A61L24/10 ,  C09J189/00 ,  A61K37/00

    CPC分类号： A61L24/106

    摘要： A tissue adhesive on the basis of human or animal proteins has a content of factor XIII and fibrinogen, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, amounting to at least 80. Furthermore, it contains a plasminogen-activator-inhibitor or plasmin-inhibitor in an amount of 20 to 2,000 KIU per ml.

    摘要翻译： 基于人或动物蛋白质的组织粘合剂具有因子XIII和纤维蛋白原的含量，因子XIII与纤维蛋白原的比例，以每克纤维蛋白原的因子XIII为单位表示，至少为80.此外，其含有 纤溶酶原激活物抑制剂或纤溶酶抑制剂，其量为20至2,000KIU / ml。

    Method of inactivating reproductive filterable pathogens in fibrinogen and factor XIII compositions
    5.
    发明授权
    Method of inactivating reproductive filterable pathogens in fibrinogen and factor XIII compositions 失效
    在纤维蛋白原和因子XIII组合物中灭活生殖可过滤病原体的方法

    公开(公告)号：US4816251A

    公开(公告)日：1989-03-28

    申请号：US775609

    申请日：1985-09-13

    申请人： Thomas Seelich

    发明人： Thomas Seelich

    IPC分类号： A61K35/14 ,  A61K35/16 ,  A61K38/16 ,  A61K38/43 ,  A61L2/00 ,  A61L2/04

    CPC分类号： A61L2/0023

    摘要： There is disclosed a method of inactivating reproductive filterable pathogens in tissue adhesives containing fibrinogen and Factor XIII, with their biologic activity being largely preserved. In order to provide a tissue adhesive preparation of human or animal origin, which exhibits a high safety with respect to reproductive filterable pathogens and whose biologic activity is largely preserved, preparations having a minimum content of 100 units of Factor XIII/g of fibrinogen are heated in the dry state in the presence of an oxygen-free inert protective gas or under vacuum.

    摘要翻译： 公开了一种在含有纤维蛋白原和因子XIII的组织粘合剂中灭活生殖可过滤病原体的方法，其生物活性大部分被保留。 为了提供人或动物来源的组织粘合剂制剂，其对生殖可过滤病原体表现出高安全性并且其生物活性被大量保留，加热至少含有100单位因子XIII / g纤维蛋白原的制剂被加热 在无氧惰性保护气体的存在下或在真空下处于干燥状态。

    Storage-stable fibrinogen preparations
    6.
    发明授权
    Storage-stable fibrinogen preparations 失效
    储存稳定的纤维蛋白原制剂

    公开(公告)号：US5962405A

    公开(公告)日：1999-10-05

    申请号：US838975

    申请日：1997-04-23

    申请人： Thomas Seelich

    发明人： Thomas Seelich

    IPC分类号： A61K9/08 ,  A61K9/14 ,  A61K38/36 ,  A61K38/43 ,  A61L24/10 ,  A61L26/00 ,  A61P43/00 ,  A61K38/00 ,  C07K5/00 ,  C07K7/00

    CPC分类号： A61L24/106

    摘要： The invention relates to storage-stable fibrinogen preparations for preparing concentrated fibrinogen solution for use as a tissue adhesive or for preparing fibrinogen solutions for other uses, for example, for infusion purposes. The fibrinogen preparations are characterized in that(i) the lyophilized preparation comprises a substance improving the solubility of fibrinogen such that the reconstitution time is up to 15 minutes, preferably less than 7 minutes, when dissolving with water at room temperature to a solution with a fibrinogen concentration of at least 70 mg/ml and(ii) the ready-to-use tissue adhesive solution obtained from the preparation forms fibrin clots having physiological fibrin structure after mixing with a thrombin-CaCl.sub.2 solution.

    摘要翻译： 本发明涉及用于制备用作组织粘合剂或用于制备其它用途的纤维蛋白原溶液的浓缩纤维蛋白原溶液的储存稳定的纤维蛋白原制剂，例如用于输注目的。 纤维蛋白原制剂的特征在于：（i）冻干制剂包括改善纤维蛋白原溶解度的物质，使得当在室温下用水溶解到溶液中时，重构时间长达15分钟，优选小于7分钟， 至少70mg / ml的纤维蛋白原浓度和（ii）从制剂获得的即用型组织粘合剂溶液在与凝血酶-CaCl 2溶液混合后形成具有生理纤维蛋白结构的纤维蛋白凝块。

    Tissue adhesive
    8.
    发明授权
    Tissue adhesive 失效
    组织粘合剂

    公开(公告)号：US4909251A

    公开(公告)日：1990-03-20

    申请号：US359346

    申请日：1989-05-31

    申请人： Thomas Seelich

    发明人： Thomas Seelich

    IPC分类号： A61L26/00 ,  A61K38/17 ,  A61K38/43 ,  A61K47/06 ,  A61L24/00 ,  A61L24/10 ,  A61P7/04 ,  A61P43/00

    CPC分类号： A61L24/106 ,  A61L24/001 ,  Y10S514/802

    摘要： A tissue adhesive in lyophilized form contains at least one biologically compatible tenside beside fibrinogen and factor XIII and optionally further proteins as well as adjuvants or additives. The presence of these biologically compatible tensides was found to shorten the reconstitution times of lyophilized tissue adhesive preparations without negatively affecting the biochemical, mechanical or biological properties of the preparation or of the tibrin formed therefrom.

    摘要翻译： 冻干形式的组织粘合剂在纤维蛋白原和因子XIII以及任选的其它蛋白质以及佐剂或添加剂之下含有至少一种生物相容的表面活性剂。 发现这些生物相容性表面活性剂的存在缩短了冻干组织粘合剂制剂的重组时间，而不会对制剂或由其形成的铁蛋白的生物化学，机械或生物学性质产生负面影响。

    Fibrin sponge
    10.
    发明授权
    Fibrin sponge 失效
    纤维蛋白海绵

    公开(公告)号：US06548729B1

    公开(公告)日：2003-04-15

    申请号：US09451361

    申请日：2000-05-26

    申请人： Thomas Seelich ,  Edgar Scheel ,  Johann Odar ,  Yves Alain Delmotte

    发明人： Thomas Seelich ,  Edgar Scheel ,  Johann Odar ,  Yves Alain Delmotte

    IPC分类号： A61F1300

    CPC分类号： A61L15/425 ,  A61L15/32 ,  A61L26/0042 ,  A61L31/046

    摘要： The invention relates to a fibrin sponge comprising a residual moisture content of at least 3%, preferably of 3 to 35%, in particular 10 to 20%, and preferably containing a blood clotting activator or proactivator, a method of preparing this fibrin sponge as well as a kit for wound gluing which comprises the fibrin sponge and a component containing a blood clotting factor. The sponge according to the present invention is suitable for hemostasis, tissue adhesion and aiding wound healing.

    摘要翻译： 本发明涉及纤维蛋白海绵，其含有至少3％，优选3至35％，特别是10至20％的残留水分含量，并且优选含有凝血活化剂或促胰岛素，将该纤维蛋白海绵制备为 以及用于伤口粘合的试剂盒，其包含纤维蛋白海绵和含有凝血因子的成分。 根据本发明的海绵适用于止血，组织粘附和辅助伤口愈合。